


First-Line Treatment Options for Patients with Stage IV Non-Small Cell Lung Cancer with Driver Alterations

Patients with stage IV non-small cell lung cancer

Nonsquamous cell carcinoma and squamous cell carcinoma




Strength of Recommendation
s Strong w Weak

This algorithm is derived from recommendations in Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations: ASCO Living Guideline. This is a tool based on an ASCO Guideline and is not intended to substitute for the independent professional judgment of the treating physician. Practice guidelines do not account for individual variation among patients. This tool does not purport to suggest any particular course of medical treatment. Use of the guideline and this tool are voluntary.

www.asco.org/living-guidelines ©American Society of Clinical Oncology 2024. All rights reserved.
 For licensing opportunities, contact licensing@asco.org

Notes. For recommendations with multiple treatment options of the same evidence quality and strength of recommendation, the decision of which agent to offer should be tailored to each patient incorporating both efficacy and toxicity. All biomarkers should be available at the time of decision-making. For alterations without targeted therapy options, refer to the non-driver alteration guideline, Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline. New active targeted therapies are anticipated soon.
Abbreviations. ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; NRG1, Neuregulin 1; NTRK, neurotrophic tropomyosin receptor kinase; PS, performance status

Second-Line and Subsequent Treatment Options for Patients with Stage IV Non-Small Cell Lung Cancer with Driver Alterations



Strength of Recommendation

s Strong **w** Weak

This algorithm is derived from recommendations in Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations: ASCO Living Guideline. This is a tool based on an ASCO Guideline and is not intended to substitute for the independent professional judgment of the treating physician. Practice guidelines do not account for individual variation among patients. This tool does not purport to suggest any particular course of medical treatment. Use of the guideline and this tool are voluntary.

www.asco.org/living-guidelines ©American Society of Clinical Oncology 2024. All rights reserved.
 For licensing opportunities, contact licensing@asco.org

Notes. Due to development of potentially targetable resistance mechanisms, every effort should be made to assess for presence of new mutation by tissue and/or blood NGS testing. If patients have received all targeted options, or if no targeted options are available, clinicians may offer standard therapy following the non-driver alteration guideline. For alterations without targeted therapy options, refer to the non-driver alteration guideline, Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline. New active targeted therapies are anticipated soon.

Abbreviations. ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; NRG1, Neuregulin 1; NTRK, neurotrophic tropomyosin receptor kinase; PS, performance status